1514888-56-2

Basic information

• Product Name: S1p receptor agonist 1
• Synonyms: S1p receptor agonist 1;1-(2-fluoro-4-(5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylic acid
• CAS NO: 1514888-56-2
• Molecular Formula: C23H24FN3O3
• Molecular Weight: 409.4533632
• Mol File: 1514888-56-2.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 566.3±60.0 °C(Predicted)
• Appearance: /
• Density: 1.268±0.06 g/cm3(Predicted)
• PKA: 2?+-.0.20(Predicted)
• CAS DataBase Reference: S1p receptor agonist 1(CAS DataBase Reference)
• NIST Chemistry Reference: S1p receptor agonist 1(1514888-56-2)
• EPA Substance Registry System: S1p receptor agonist 1(1514888-56-2)

Safety Data

• Hazardous Substances Data: 1514888-56-2(Hazardous Substances Data)

Usage

General Description

S1P receptor agonist 1 is a chemical compound that acts as an agonist for the sphingosine-1-phosphate (S1P) receptor, specifically targeting the S1P1 receptor subtype. S1p receptor agonist 1 binds to the S1P1 receptor and activates it, leading to a series of downstream signaling events in the cell. S1P1 receptors are known to play a role in various physiological processes such as immune function, vascular development, and neural cell migration. Therefore, S1P receptor agonist 1 has the potential to be used in the development of therapeutic agents for conditions such as autoimmune diseases, cardiovascular disorders, and neurological disorders. Additionally, it may have applications in research and drug discovery related to S1P receptor signaling.

Upstream product

• 219873-06-0 3-fluoro-4-(hydroxymethyl)benzonitrile 
• 188582-62-9 4-bromo-2-fluorobenzyl alcohol 
• 179232-29-2 methyl 4-bromo-2-fluorobenzoate 
• 36476-78-5 3-azetidinecarboxylic acid 
• 38861-88-0 4-isobutylbenzoic acid 

Relevant articles and documents

ADDITION SALT OF S1P1 RECEPTOR AGONIST AND CRYSTAL FORM THEREOF, AND PHARMACEUTICAL COMPOSITION

Disclosed in the present application are a salt form and a crystal form of an S1P1 receptor mediated disease or symptom drug 1-{2-fluoro-4-[5-(4-isobutylphenyl)-1,2,4-oxadiazole-3-yl]benzyl}-3-azetidinecarboxylic acid (formula A). Also disclosed in the present invention are a preparation method for the salt form or the crystal form, a pharmaceutical composition of the salt form or the crystal form, and use of the salt form or the crystal form in the preparation of a drug for treating and/or preventing an S1P1 receptor mediated disease or symptom.

IMMUNE ADJUSTMENT COMPOUND, USE THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention provides a compound represented by formula I, wherein R is a halogen element or a C1-C6 alkyl group. The compound has S1 P1 receptor agonist activity and selective specificity and has obviously-shortened half-life in-vivo, and therefore the compound is a high-quality second-generation S1P1 receptor agonist. The present invention also provides a use of the compound in preparing medicine for treating diseases or symptoms mediated by an S1P1 receptor, a pharmaceutical composition comprising the compound, and uses of the compound and the pharmaceutical composition in treating diseases or symptoms mediated by the S1 P1 receptor.